Biologics: Targets and Therapy

Biosimilars, Biobetters, and Bioparallels

Looking back on almost three decades of biosimilars and despite their difficult start in Europe in 2015, biosimilars are solidly embedded in patient care and have become a mainstay in human therapeutics – at least in high income countries. Being equivalent in efficacy/effectiveness, safety and (mainly) priced lower than the originators they reference, biosimilars enable savings, expanded patient access, and greater patient equity.